

Table 11 - Suggested Paediatric PEP regimens (Adapted from [CHIVA 2021](#))

Weight/Age (years)	Preferred PEP	Alternative PEP	Notes
>40kg / 12 years	Raltegravir 400 mg bd +emtricitabine 200mg/tenofovir disoproxil* (TDF) 245mg	3 rd Agent: dolutegravir 50mg od NRTI: emtricitabine 200mg/tenofovir alafenamide 25 mg OR lamivudine 150mg/ zidovudine 300mg	*Tenofovir disoproxil should not be used in the presence of renal insufficiency. Alternative backbones include lamivudine with zidovudine or emtricitabine / tenofovir alafenamide.
>= 6 years AND >=25kg to <40kg	Dolutegravir + lamivudine + zidovudine	3 rd agent: Kaletra®(lopinavir/ritonavir) OR raltegravir NRTI: lamivudine + tenofovir disoproxil* OR emtricitabine 200mg/tenofovir alafenamide 25 mg	For both dolutegravir and raltegravir different formulations are NOT bioequivalent. (see dosing table)
<6 years and < 25kg	Dolutegravir + lamivudine + zidovudine	3 rd agent: Kaletra®(lopinavir/Ritonavir) OR raltegravir NRTI: lamivudine + tenofovir disoproxil	Use raltegravir (Isentress® chewable tablets) when available. For both dolutegravir and raltegravir different formulations are NOT bioequivalent.
<3kg or <4weeks	Seek expert advice		